Data from two ITN transplant trials will be reported at the upcoming American Transplant Congress (ATC) meeting in Boston, MA on June 2-6, 2012.
Preliminary results from the A-WISH ITN030ST study, which examines feasibility of immunosuppression withdrawal in hepatitis C or non-immune non-viral liver transplant patients, will be reported in the abstract:
-
Initial outcomes of ITN030ST: Early post-liver transplant immunosuppression withdrawal (Abraham Shaked, MD, PhD, University of Pennsylvania).
Additionally, updated data on the previously-published B-cell signature from the ITN507ST “Study of tolerant kidney transplant recipients,” including the presence of the signature in a new cohort of tolerant patients and the stability of the signature over time, will be reported in the abstract:
-
Refinements of the transcriptional B cell ‘signature’ associated with clinically tolerant renal transplant recipients (Kenneth Newell, MD, PhD, Emory University).